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A  significant advance  in  the  knowledge of the  mechanism of staphylocoagulase 
action was the discovery by Smith and Hale (1) of a factor in plasma and in tissues 
with which the coagulase reacts. This  agent was named  "activator"  by the British 
investigators,  and  the  "coagulase-reacting  factor,"  or  "C.R.F."  by others  (2-4). 
Evidence has been presented that C.R.F. is distinct from any of the blood components 
known at present  to be essential  for physiological clotting  (2,  3).  Separation  from 
prothrombin has been accomplished by Seitz filtration, and C.R.F. has been identified 
with the globulin moiety of plasma (3). Contrary claims, linking C.R.F. with albumin 
(5) and fraction IV-4 of Cohn (6) resulted from the use of too weak coagulase prepara- 
tions which permitted a coagulase inhibitor to mask the C.R.F. activity of globulins, 
and from reliance on ammonium sulfate fractionation which fails to eliminate C.R.F. 
from albumin. 
C.R.F.  of plasma,  titrated  against  a  standardized  coagulase preparation  (7),  re- 
mains constant for many months at ordinary ice box temperatures. It has often been 
observed (8),  however, that the conversion of plasma to serum may lead to signifi- 
cant changes in the C.R.F. All previous Standardizations,  therefore, were based on 
the use of plasma rather than serum.  It was further noted  (8)  that the strength of 
the coagnlase was critical: thus, with highly active eoagulase preparations,  plasmas 
consistently had more C.R.F. than the derived serum. When weaker coagnlase prep- 
arations were used, however, and the concentrated levels of plasma and serum tested, 
the clotting time of serum might actually be more rapid than that of plasma. 
Recent unpublished observations with Dr. A. B. Stavitsky have indicated striking 
fluctuations in the C.R.F.  of serum under certain experimental  conditions. Rabbits 
were sensitized with a specific antigen, and at suitable time intervals sera and plasmas 
were collected after a  challenge inoculation with  the same antigen.  Plasma C.R.F. 
titers  remained  constant, while striking  changes were noted  in the  C.R.F.  content 
of the sera. This suggested that either C.R.F. is actively influenced by the physiologi- 
cal clotting process, or that  it is passively adsorbed  on  the fibrin  clot. The recent 
report of Duthie and Lorenz (9)  implicating calcium ions in the  loss of C.R.F.  in 
serum points to the former alternative, namely that the C.R.F. changes result from 
an active interaction with the agents concerned in physiological clotting. 
The fact that  the coagulase-reacting factor of plasma is actively influenced 
by physiological clotting assumes special interest  in that it indicates some in- 
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teraction  between  the  participants  of  two  diverse  clotting systems.  Whether 
this  reaction  is  fortuitous,  or  actually  has  some  significance  in  physiological 
clotting,  is at present  undetermined.  The object of this report  is to elucidate 
the mechanism of C.R.F.  loss when plasma  is converted to serum. 
Materials and Methods 
Coagulase.--Staphylocor,  cus aureus No. 104 was grown in 200 ml. lots in 1 liter Roux hot- 
ties in a  brain-heart infusion medium (Difco) modified by the addition of a mixture of ions 
(7).  After 5 days at 37°C.,  the cells were removed by centrifugation, and  the supematant 
solution was acidified to a pH of 5.2, using 5 ~  acetic acid. The solution was chilled to 0°C., 
and cold absolute methyl alcohol was added to a final concentration of 20 per cent, maintain- 
ing the temperatures below +1°C. at all times. After forming in a  cold bath at  --5°C. for 
12 to 18 hours, the precipitate was centrifuged in the cold, and was resuspended and partially 
dissolved in 0.15  M sodium acetate, followed by the cautious adjustment of the pH to 7.4 
with  1 K NaOH. The insoluble precipitate was again centrifuged, and active coagulase eluted 
with further  small increments of 0.15  M sodium acetate. The active supernatant  solutions 
were pooled, and then diluted with an equal volume of distilled water. The pH was adjusted 
to 5.4 with 1 M acetic acid, and precipitation carried out with methyl alcohol to a final con- 
centration of 17 per cent, observing the same temperature precautions as before. The pre- 
cipitate was then handled as after the first alcohol treatment.  If necessary, a  third cycle of 
alcohol precipitation was carried out at a pH of 5.3 in 0.075 M sodium acetate buffer and at 
a concentration of methyl alcohol of 20 per cent. This procedure generally gave purification 
of about 125 times over the original cell-free culture supernatant, and  entailed a  loss of 50 
per cent of the initial coagulase activity. Purification was determined by activity to nitrogen 
ratios.  The coagulase, now a  water-clear solution, was either lyophilized after dialyais, or 
maintained in the deep freeze unit at about  -15°C. The use of methyl alcohol here is anal- 
ogous to the procedures developed by Pillemer and his associates (10) for the purification of 
bacterial toxins. This method was preferred to a  scheme of coagulase purification previously 
developed (11) because of its greater simplicity and because the significantly higher purifica- 
tion attained by the older method was not necessary for the present purpo6es.  This coaguiase 
clotted  an  equal  volume of  "non-inhibitory" plasma  (7)  in 20 seconds,  or, when diluted 
1:10, 240, the coagulase still clotted an undiluted, non-inhibitory plasma in 24 hours. Reac- 
tion of this coaguiase with an equal volume of fibrinogen and plasma diluted 1:4500 generally 
led to coagulation within 15 minutes. In the tests, the coagulase was  generally diluted  1:4 
or 1:5 before use. 
Tbrombopia.~lin.--Prepared from acetone extracts of rabbit brain essentially as developed 
by Quick (12).  0.3 gin. of the powder was suspended in 10 ml. of veronal buffer (v.i.), heated 
at 50-55°C. for 10 minutes, and the supernatant material used. 
Verona/Buffs'.--0.1 M sodium diethylbarbiturate was adjusted to a  pH of 7.05 with 0.1 
K HCI, and 5.67 gin. of NaC1 was added per liter of buffer.  This solution was  then  diluted 
with an equal volume of physiological saline solution (13). 
Prothromb/n.--A  purified  product,  lot  470509,  containing  11,500  units  per  nag. of 
tyrosine, prepared from bovine plasma, and kindly supplied by Dr. Walter H. Seegers, was 
used in a concentration of 0.2 rag. per ml. of veronal buffer at a pH of 7.05. 
F~tor  V.--In  the main,  the technique of Owren  (13)  was followed.  100  ml. of freshly 
drawn oxalated bovine plasma was freed of prothrombin activity by 5 Seitz filtrations. The 
plasma was then diluted with an equal volume of distilled water, and  100 ml. of saturated 
ammonium sulfate was added  (70.6 gin. of ammonium sulfate plus 100 ml. of water at 0°C. 
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ment of  I00 ml. of saturated ammonium sulfate was added to the supernatant solution to 
make a  solution saturated 50 per cent with respect to ammonium sulfate. The precipitate 
was centrifuged, dissolved in saline, and thoroughly dialyzed against distilled water.  After 
dialysis, the solution in the casing was acidified to a  pH of 5.3,  and the precipitate which 
formed was collected by centrifugafion and dissolved in 20 ml. of veronal buffer at pH 7.05 
and preserved at -15 ° to -20°C. For use one part of this was diluted with 9 parts of veronal 
buffer. 
Fibrinogen.--Armour's  fraction I, bovine fibrinogen, was made up at a  concentration of 
250 rag. per cent in veronal buffer at a pH of 7.05. 
Bu~er for C.R.F.  Ti~rc~ions of Diluted Pos~con~ersion Samples.--Veronal  buffer (see above) 
containing 0.005 M sodium citrate and 2 rag. of bovine albumin (Armour) per ml. 
General Method of Measuring Residual C.R.F. after Prothrombin Conversion.--(For  specific 
details and modification, see the individual protocols.) 
The various materials employed, e.g. fresh plasma, thromboplastin, factor V, etc., were 
maintained in the deep freeze unit at -15°C. and fresh dilutions were made for each day's 
experiments. The preliminary incubation mixture consisted of the plasma and various added 
factors involved in prothrombin conversion made up to a constant volume of 1 ml. in veronal 
buffer. Controls, containing the same ingredients, but no added calcium, were set up in the 
same manner. Such clots as formed were shaken loose and the mixtures allowed to stand in 
the 37  ° bath for 1 to 2 hours, after which time thrombin had disappeared and no further 
change in residual C.R.F. levels could be detected. 
The reacted samples were then further diluted in veroual-citrate-albumin buffer to give 
plasma or serum dilutions of 1:200, 1:400, and 1:1000. To 0.5 ml. portions of these mixtures, 
0.5 ml. fibtinogen solution and 0.5 ml. ceagulase were added, and the tubes incubated under 
constant observation at 37°C.,  the appearance of the first wisp of fibrin being taken as the 
C.R.F. clotting time. Thrombin controls, omitting coagulase, were always carried out simul- 
taneously with the test. 
RESULTS 
The Effect of Blood Coagulation on C.R.F. 
The object of this experiment was to follow the changes in C.R.F. as freshly 
drawn blood was allowed to clot. 
Venous blood was collected with a siliconized  x needle and syringe, and 2 ml. lots were dis- 
tributed in a  series of lusteroid tubes. The first of these tubes contained 0.2 rid. of 0.1 M so- 
dium citrate and served as the plasma control. At various intervals of time, the same amount 
of citrate was added to the other tubes to stop further prothrombin conversion. The cells 
were  removed by centrifugation immediately,  and  the supernatant solutions diluted with 
veronal buffer, in a ratio of 0.1 ml. of serum to 1.9 ml. of buffer. From these master dilutions, 
two further dilutions were made for the C.R.F. tests and for the prothrombin determinations. 
(a)  For C.R.F.  determination, the master dilution was further diluted to a  final level of 
1:320 with veronal-citrate-albumin buffer, and then reacted with coagulase and fibrinogen 
using 0.5 ml. of each reagent in the final test mixture. The controls for thrombin were nega- 
five. 
(b)  For the prothrombin determination, the master dilution was further diluted  1:3 in 
the  thromboplastin-calcium mixture.  After  3  and  6  minutes respectively,  0.4  ml.  of  this 
sample was added to 0.I ml. of fibrinogen in 10 X  75 ram. tubes, and the clotting times were 
measured. 
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The results are summarized in Table I. It will be noted that there is a  pro- 
gressive loss of C.R.F. as prothrombin is converted, so that the clotting time 
was four times longer in the sample citrated 1 hour after the blood was drawn 
than in the control sample. Other similar experiments using a  variety of dilu- 
tions  of serum  were  confirmatory of  these  findings.  It  was  also  found  that 
heparin,  like citrate, will prevent  C.R.F.  loss when  added to the sample im- 
mediately. 
TABLE I 
The Effec~ on C.R.F. Clotting Time of the Addition of Citrate at Various Time Inlervals to 
Freshly Drawn Blood 
Time elapsed before citrating 
0 
5 
10 
15 
2O 
30 
4O 
60 
120 
CRF clotting  time 
m/n. 
4~ 
4~ 
s 
5½ 
5~ 
sl 
19 
19 
Prothrombin time (modified 
two stage) 
$¢~°* 
27 
31 
37 
57 
95 
352 
704 
* Average of 3 and 6 minute readings. 
The  Effect  of Plasma  Age,  Factor  V,  and  Calcium  on  C.R.F.  Clotting  Time 
after Plasma to Serum Conversion 
The age of the human plasmas used in this study varied considerably, since 
for the most part these were blood bank discards. It therefore seemed possible 
that the age of the plasmas might play a  role in the variations encountered in 
C.R.F.  activity from  sample  to  sample  upon  the  conversion  of  plasma  to 
serum. This even seemed probable from the observation that the serum C.R.F. 
of freshly drawn blood was often considerably lower than that of older samples. 
To test the possibility further, a  freshly  drawn sample of blood was citrated, the cells 
were removed by centrifugation,  and the plasma divided into two portions: one of these was 
immediately placed in a deep freeze unit at about --15°C., while the other sample was main- 
tained in the ice box at 5°C. The plasmas were kept for 3 weeks, and the sample maintained 
at --15  ° will be referred to as "fresh" plasma, while the specimen kept at 5  ° for 3 weeks will 
be called "old." 
It has been shown that Owren's factor V may lose activity when stored at ordinary ice 
box temperatures (13). It therefore  seemed possible that variations in the activity of factor 
V might be implicated in the C.F.R. loss upon the conversion of plasma to serum, and might 
therefore be involved in the differences of behavior of plasmas of varying age. Factor V was 
therefore prepared from fresh bovine plasma (see Methods)  and  its effect on  the C.R.F. re- MORRIS  TAGER  AND  ANNE  L.  LODGE  77 
sidual studied. Parallel titrations were carried out with and without the presence of added 
calcium in the prothrombin conversion mixture. 
The results are summarized in Table II. A comparison of the  C.R.F. clot- 
ting times of  test A when calcium ions were added to the preliminary  incuba- 
tion mixture with  the  C.R.F.  clotting times  of control B  in  which  calcium 
ions were  omitted from the  incubation mixture,  immediately makes evident 
the essential nature of these ions for the subsequent C.R.F. loss. The hypothe- 
sis  that the age of the plasma is involved was substantiated,  since the serum 
derived  from the  aged  plasma  showed  significantly  greater  C.R.F.  activity 
than that from the fresh plasma (clotting time of 8 minutes vs.  17.5 minutes). 
TABLE II 
The Effect of Plasma Age, Factor V, and Calcium on the C.R.F. Clotting Time after Plasma to 
Serum Conversion 
Test No. 
ml. 
1  0.1 
2  0.1 
3  0.1 
4  0.1 
5  0 
6  0 
Prothrombin conversion incubation  Residual C.R.F. clotting time at final 
mixture*  plasma dilutions below: 
Fresh plasma  Factor V 
~,7  i  ~i_-i 
0  0 
0  0.1 
0  0.2 
0  0.3 
0.1  0 
0.1  0.2 
Thrombo- 
plastin 
ml. 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
Testa 
(with calcium)~ 
,:~  _,:,2% 
26~  41 
31  53 
31  57 
17]  29 
37½  52] 
Control B 
(no calcium) 
i  1:600  1:1200 
3½  4t 
3½  4~ 
3t  41 
3t  4! 
3]  41 
3½  4| 
* All volumes made up to 1 ml. with veronal buffer. 
:~ 0.05 ml. of 0.1 ~ CaCI, added to the prothrombin conversion  incubation mixture. 
Thrombin controls  of A and B: no clot at end of 1 hour when coagulase omitted. 
However, when factor V was added to the aged plasma before the conversion, 
the serum thus obtained had much less residual C.R.F. activity. 
It is of interest  to note that  the variations in the components of the pro- 
thrombin conversion mixture were not of sufficient magnitude to produce any 
effect on the one stage prothrombin clotting time of these samples, which fell 
between  50  and  55  seconds.  In spite  of  this,  however,  striking  effects were 
produced on the residual C.R.F. after the plasma to serum conversion. 
The Effect of the Preliminary  Heating  of Plasma and the Restoration  of Factor 
V  on the Residual C.R.F. after Plasma to Serum Conversion 
Since factor V is known to be more thermolabile than prothrombin (13,  14) 
or C.R.F.  (3), advantage was taken of this property to determine the extent 
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its conversion to serum. The plasma was therefore heated at 51°C. for various 
times up to 30 minutes, a  treatment which  leaves  C.R.F. and prothrombin 
activity virtually unimpaired. Although the C.R.F. titrations were carried out 
in the usual manner, the results have been expressed in terms of per cent ac- 
tivity by extrapolating arithmetically several clotting times. It will be noted 
(Chart 1)  that heating the plasma for 15  to 30 minutes virtually abolished 
C.R.F. loss after conversion. 
This system, further, lent itself to assaying quantitatively the sensitivity of 
the C.R.F. system to various amounts of factor V. One unit of factor V  con- 
sisted of 0.005 ml. of the preparation. It is evident that the addition of 2 units 
of factor V resulted in a C.R.F. loss of over 80 per cent after conversion,  while 
increasing factor V to 10 units resulted in a 95 per cent C.R.F. loss. 
I00 
80 
40 
20 
l'  i 
I 
/ 
ig  3z 
MINUTES PLASMA 
HEATED AT 51"C. 
~"'~ RESIDU~  ORE 
o---¢RESIDUIg. PROTHROMBN 
z  4  6  8  ~o 
UNITS OF FACTOR "~" ADI~.~) 
TO PLASMA  HEATED  AT 51-30 MIN. 
CH.~m'r 1.  C.R.F. and prothrombin residual activity after heating plasma and restoring 
factor V. 
Other titrations were carried  out in which factor V was heated and then 
added to unheated and to heated plasma samples. The results were entirely 
confirmatory of the data here presented. 
The prothrombin consumption studies  indictated on Chart 1 will be dis° 
cussed below. 
The Relation of Thromboplastin  to C.R.F. Loss after Plasma to Serum 
Conversion 
Since calcium is required  for the C.R.F. loss during serum formation (9), 
and since factor V exerts a profound effect on this loss in the presence of an 
otherwise complete conversion system, it was of interest to investigate the role 
of thromboplastin in this reaction.  A satisfactory test system for this purpose 
was furnished by a  plasma which  had been  previously clotted with a  large 
amount of thrombin (300 units per ml. of purified  bovine  thrombin~). Ware 
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and Seegers (15) have shown that such treatment of a plasma results in a loss 
of AC globulin (or factor V), while prothrombin is not similarly affected. Stud- 
ies here have shown that the C.R.F. content is likewise unimpaired. The data 
of Table III show the effects of recalcifying such a  sample with the addition 
of factor V  and thromboplastin alone and  in combination. The addition of 
thromboplastin alone  (No.  4)  caused no  C.R.F.  loss,  since  this sample  was 
now deficient in factor V. While the restitution of factor V alone (No. 5) caused 
only a slight change in the clotting time, from 3 to 43 minutes, the combina- 
tion of the two factors (No. 6) resulted in a  residual C.R.F.  clotting time of 
45  minutes,  indicating  the almost complete removal of C.R.F.  It should be 
noted that the original untreated plasma apparently contains its full comple- 
ment of these conversion factors since the addition of calcium alone (No. 2) 
TABLE HI 
The Relation of Thromboplastin to C.R.F. Loss after Plasma to Serum Conversion 
No. 
Prothrombin conversion incubation mixture* 
Untreated 
plasma 
0.5 
0.5 
0 
0 
0 
0 
Thrombin-  Thrombo- 
clotted plasma  plastin 
~l.  sd. 
0 
0 
0 
0.25 
0 
0.25 
0 
0 
0.5 
0.5 
0.5 
0.5 
Factor  V  __C~hlx  1:600 
ml. 
o  31 
0  0.025  40 
0  0  3 
0  0.025  3 
o. 1  0.025  4½ 
0.1  0.025  45 
Residual C.R.F.  dotting 
time at final plasma dilutions 
below 
1:1200  1:3000 
rain.  rain. 
si  8t 
41  H 
4½  7i 
7  13 
* All mixtures made up to 1 ml. total volume with veronal buffer. 
Thrombin controls on test, by omitting coagulase: no clots in 1 hour. 
was sufficient to potentiate a  comparable C.R.F.  loss  (clotting time 40 min- 
utes). 
It would thus appear that not only was factor V greatly reduced by the throm- 
bin treatment, but the thromboplastic activity was impaired,  since only the 
restoration of both these substances permits the system to regain its full poten- 
tial as far as C.R.F. consumption is concerned. 
The Effect on C.R.F. Loss of the Removal of Protkrombin by Seitz Filtration and 
of the Restoration of Protkrombin to the Preliminary Incubation Mixture 
For the present, the best established function of factor V is its capacity to 
accelerate prothrombin  conversion. The participation  of  calcium,  factor V, 
and of thromboplastin in this reaction makes it increasingly obvious that it is 
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the  effect on C.R.F.  This problem was  studied by  the  use  of Seitz-filtered 
plasmas from which demonstrable prothrombin activity had  been  eliminated 
but which retained substantial amounts of C.RF. and some factor V. Restora- 
tion of prothrombin was then accomplished by the addition of highly purified 
bovine  prothrombin of Dr.  Seegers,  which is essentially free of C.R.F. The 
results,  summarized in Table IV,  indicate that indeed no C.R.F. loss  occurs 
when prothrombin is unavailable (Nos. 1 and 2). The addition of prothrombin 
led to over a  twofold prolongation of  the  residual  clotting time (Nos.  3,  4, 
and 5), since unquestionably some factor V activity was present in the plasma. 
When, however, both  prothrombin and  factor V were  added,  over five-fold 
prolongation of the clotting time resulted (No. 6). 
TABLE IV 
The Effect on C.R.F. Loss of the Removal of Prothrombin  by Seitz Filtration  and the Restoration 
of Prothrombin  to the Prdlminary Incubation  Mixture 
Prothrombin conversion incubation  Residual C.R.F.  clotting time at final plasma 
mixture*  dilutions below 
No.  ~ .....  Test A  (with calcium):~  Control  (no calcium)  Pro- 
Plasma  throm- 
(Seitz)  bin 
sd.  st/. 
0.1  0.1 
0.1  0 
0.1  0.1 
0.1  0.2 
0.1  0.4 
0.1  0.I 
Facto 
ml, 
0 
02 
0 
0 
0 
0.2 
r  Throm- 
boplastin  1:600  1:1200 
ral.  rain.  rain. 
0.1  2½  4 
0.1  2i  3~ 
0.1  51  9 
0.1  5i  9 
0.1  5]  9 
0.1  12{t  20 
1:3000 
mln. 
7 
7~ 
19 
19 
20 
1:600  I 
mln. 
2½ 
2,~ 
2½ 
2½ 
21 
:oo 
m  __ 
$. 
4½ 
1:3000 
rain. 
7 
si 
7 
7i 
7 
* All mixtures made up to total volume of 1 ml. with veronal buffer. 
~/0.05 ml. of 0.I ~  CaCls added tothe prothrombin conversion mixture. 
Thrombin controls of A and B: no clot at the end of 1 hour when coagulase omitted. 
Prothrombin Consumption  in Relation to C.R.F. Consumption  after 
Prothrombin Conversion 
Since the process of prothrombin conversion is implicated in the residual 
C.R.F. levels, it became of interest to establish whether any parallelism could 
be demonstrated between prothrombin and C.R.F. consumption. The experi- 
ment is presented in Chart 1. 
The prothrombin consumption test was based on a  modified two stage method. The in- 
cubation mixture consisted of 0.1  ml. of a  suitable dilution of plasma or test mixture, 0.2 
ml. of thromboplastin, 0.04 ml. of 0.02 ~  CaCI~, 0.2 ml. of factor V containing 20 units per 
ml., and buffer to a final volume of 2 ml. The serum or plasma concentrations were adjusted 
to give clotting times from 15 to 100 seconds. This mixture was incubated for 2, 4, 6, 8, and 
10 minutes respectively, and was reacted in a  volume of 0.2  ml. with an equal volume of 
fibrinogen to determine the clotting times. The maximum thrombin time was taken to be the MORRIS  TAGER  AND  ANNE  L.  LODGE  81 
lowest constant value obtained. The per cent of prothrombin activity of the sera was cab 
culated from a base line determined by plotting several dilutions of the original plasma against 
the dotting time. 
It is apparent that under the conditions  of the test, a close parallelism  be- 
tween prothrombin and C.R.F. consumption has been demonstrated. 
The  Effect  of  the  Addition  of a  Prothrombin  Conversion  Mixture  in  Various 
Stages of Completion to a Seitz-Filtered Plasma as the C.R.F. Source 
In preceding experiments, prothrombin, ancillary conversion factors,  and 
the C.R.F. were incubated together, and the effect on the C.R.F. clotting time 
determined. The present experiment was  designed  to  evaluate the  effect  of 
TABLE  V  Effect  of the Addition  of a ProthromMn  Conversion  Mixture  at Various  Stages  to C.R.F. 
Preincubation  time of conversion mixture 
before addition of plasma 
m/n. 
o 
½ 
1 
2 
5 
10 
2o 
4o 
Control* ......................... 
Thrombin times of conversion mix- 
ture at dilutions below 
Residual C.R.F. clot- 
ting time at final  plasma 
dilutions below 
1:20  1:40  1:100  1:600 
i  mii'~l ] i~  rain.  min.i  rain.12121214  5~: 
2¼  4½  10  4 
2t  4½  10½  3 
--  --  --  2½ 
1:1200 
m/m. 
21 
22 
21 
19 
20 
III 
Sl 
51 
31 
* No calcium added to conversion mixture. 
the developing prothrombin conversion on C.R.F. by sampling from the con- 
version mixture at intervals of time and adding these samples to a prothrombin- 
free, Seitz-filtered plasma containing the C.R.F. 
The reaction mixture was composed of 1 ml. of Seegers' bovine prothrombin, 1 ml. of fac- 
tor V, 2 ml. of thromboplastin, 0.5 ml. of 0.1 ~ calcium chloride, and 4.5 ml. of veronal buffer. 
As the mixture incubated at 37°C., 0.9 ml. lots were withdrawn at the indicated time inter- 
vals (Table V), and were added to 0.1 ml. of a prothrombin-free, Seitz-fiitered plasma. These 
were then incubated for 2 hours, and tested for C.R.F.  by the usual addition of coagulase 
and fibrinogen at a final dilution of 1:600 and 1:1200 of the plasma in veronal-citrate-al- 
bumin buffer. Thrombin  times were determined on the same dilutions by the addition  of 
fibrinogen, but omitting the coagulase. 
The data of Table V indicate that as the reaction of the preincubation mix- 
ture is allowed to go to completion, there is a diminishing effect on C.R.F. loss 
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proaches completion, as indicated by the piling  up of thrombin and the con- 
sequent shortening of the thrombin time, the subsequent C.R.F. loss progres- 
sively diminishes.  It will be noted that a rather sharp break  took place after 
5 minutes  (from 5~ to  12 minutes at  1:600),  while  after 40 minutes of pre- 
incubation the C.R.F. dotting time approaches that of the control in which cal- 
cium was withheld to prevent any prothrombin conversion from taking place. 
The Effect of tke Fibrin Clot on C.R.F. Loss after Plasma to Serum Conversion 
The possibility was considered  that the C.R.F. loss in the course of serum 
formation might be due to adsorption on the fibrin clot. That this is not the 
ease is evident from Table HI. It can be seen (Nos. 1 and 3) that the C.R.F. 
activity is quite unimpaired after the plasma has been clotted by a large amount 
of thr0mbin; indeed, it is slightly enhanced probably because of the removal 
of some inhibitors.  It is not until this defibrinated plasma (No. 6) is treated 
with  the prothrombin  converting reagents  (calcium,  factor V, and  thrombo- 
plastin)  that the loss of C.R.F. occurs, although no clot formation intervenes 
in this process. 
Other experiments in which plasma was defibrinated with smaller amounts 
of thrombin and in which purified fibrinogen  was restored to the system, con- 
finned these observations. 
DISCUSSION 
There is ample evidence to support the view that staphylocoagulase action 
is distinct from the physiological  mammalian blood-clotting process.  In favor 
of this contention, one may cite the following observations:-- 
1.  Anticoagulants,  such as citrate and  oxalate which depress ionized  cal- 
cium, do not block coagulase  activity (16). 
2.  Coagulase acts in the presence of hepafin, which is assumed to have anti- 
prothrombic activity as well as the ability to block thrombin-fibrinogen  in- 
teraction (17-19). 
3.  C.R.F.  has  been  dissociated  from  prothrombin  by  Seitz  filtration  of 
plasma (3, 9, 20, 21). If C.R.F. is available, coagulase will still clot blood even 
though all conventional tests of prothrombin activity are negative. 
4.  There is a natural dissociation of prothrombin and C.R.F. in some ani- 
mal hosts (1, 3). This may be because of an inherent lack of C.R.F., or may 
represent a masking of the coagulase-C.R.F, reaction by inhibitors. 
5.  Attempts to identify C.R.F. with any of the known blood components 
which function in physiological  clotting have been unsuccessful. 
In the light of some evidence (1, 22) that an intermediate complex may be 
formed, one may tentatively consider that the coagulase reaction includes  the 
following steps:-- 
Staphylocoagulase +  C.R.F.  ffi  intermediate complex (called "coagulase thrombin" by 
Miale (22)) 
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The present observations, as well as those of Duthie and Lorenz (9), bear 
directly on the problem of the relation of the two clotting processes.  These 
studies indicate an interaction between the two systems in so far as prothrom- 
bin conversion exerts a profound effect on residual C.R.F. titers. Any system 
favoring effective prothrombin  conversion favors maximal  C.R.F.  loss;  con. 
versely, factors which  may hinder  prothrombin  conversion  will  reduce  this 
C.R.F. loss. Obviously, all the components required for prothrombin conver- 
sion must be on hand, and a deficiency in any of the essential components of 
prothrombin  conversion or interference with  their function will  be reflected 
in the residual C.R.F. clotting times. The most marked C.R.F. loss (from 90 
to 98 per cent) was observed following the conversion of fresh human plasma 
to  serum,  and  in  the  presence  of  an  effective concentration  of  accelerator 
globulin  (factor V), provided adequate amounts of thromboplastin  and  cal- 
cinm were at hand. If prothrombin is removed, the subsequent C.R.F. loss is 
abolished. No support was found for the possibility that  adsorption on the 
fibrin was significantly  implicated in the C.R.F. loss. 
An increasing  number of factors which accelerate prothrombin  conversion 
have been described, although some of these may prove to be identical. Alex- 
ander (23, 24) has described a plasma component SPCA (serum prothrombin 
conversion accelerator) which he regards as distinct from Seegers' AC globulin 
and Owren's factor V, but which accelerates prothrombin conversion only in 
the presence of plasma AC globulin.  In unpublished observations, utilizing  a 
partially purified sample of SPCA kindly supplied by Dr. Alexander,  it was 
found, as might have been anticipated from the reported properties of SPCA, 
that this agent alone had only little effect on the C.R.F. titers after prothrom- 
bin conversion, an effect which might weU have been due to trace contamina- 
tion with AC globulin.  This is consistent with Alexander's claim that  SPCA 
alone is relatively inert when acting on purified prothrombin. 
Milstone (25, 26) has presented a three stage analysis of blood clotting, in- 
volving  (a)  the  conversion  of prothrombokinase  to thrombokinase,  (b)  the 
conversion of prothrombin to thrombin, and (c) the reaction of thrombin with 
fibrinogen  to yield fibrin.  Calcium is of importance for the first two stages, and 
evidence has been presented further  that  "thrombokinase" may be essential 
for both the conversion of prothrombokinase to thrombokinase as well as for 
the  conversion  of prothrombin  to  thrombin,  rather  than  that  thrombin  or 
lipoid thromboplastin normally functions in this regard. In the present studies, 
the  thromboplastin  has been used to activate prothrombin  conversion,  and 
the  three  stage  scheme of Milstone  has  not  been applied.  Nevertheless, it 
appears probable that  the C.R.F.  loss is related  to Milstone's second phase 
rather than  the first,  if for no other reason than  that an incubation mixture 
containing everything necessary for conversion except prothrombin  does not 
lead to C.R.F. loss. 
At present,  the functions of C.R.F.  are not known other than its reaction 84  COAGULATION OF BLOOD BY STAPHYLOCOAGULASE 
with staphylocoagulase. Since C.R.F. is apparently consumed during effective 
prothrombin conversion, further studies of the functional significance of this 
globulin in physiological clotting and in disease may prove of interest. In so 
far as  this  reaction is a  sensitive indicator of disturbances  in prothrombin 
conversion, it offers a new variable which might be put to use in the study of 
disturbances of prothrombin conversion. 
S~ARY 
The conversion of plasma to serum results in a variable loss of the coagulase- 
reacting factor (C.R.F.) of the plasma. 
The C.R.F. loss is incurred during the process of prothrombin conversion: 
conditions which favor the most effective prothrombin conversion result  in 
maximal C.R.F. loss, while factors which interfere with prothrombin conver- 
sion spare the C.R.F. 
In  a  system containing an  adequate  concentration of calcium,  thrombo- 
plastin, and prothrombin, the C.R.F. loss reflects the amount of prothrombin 
conversion-accelerating substances (factor V or AC globulin). 
If fibrin clots are produced directly by thrombin, and prothrombin conver- 
sion is excluded, there is no significant C.R.F. loss. 
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